|
Title
|
|
|
|
Beyond CSF and neuroimaging assessment : evaluating plasma miR-145-5p as a potential biomarker for mild cognitive impairment and Alzheimer's disease
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Alzheimer's disease (AD) is the most common cause of dementia. New strategies for the early detection of MCI and sporadic AD are crucial for developing effective treatment options. Current techniques used for diagnosis of AD are invasive and/or expensive, so they are not suitable for population screening. Cerebrospinal fluid (CSF) biomarkers such as amyloid beta 1-42 (A beta 1-42), total tau (T-tau), and phosphorylated tau181 (P-tau181) levels are core biomarkers for early diagnosis of AD. Several studies have proposed the use of blood-circulating microRNAs (miRNAs) as potential novel early biomarkers for AD. We therefore applied a novel approach to identify blood-circulating miRNAs associated with CSF biomarkers and explored the potential of these miRNAs as biomarkers of AD. In total, 112 subjects consisting of 28 dementia due to AD cases, 63 MCI due to AD cases, and 21 cognitively healthy controls were included. We identified seven A beta 1-42-associated plasma miRNAs, six P-tau181-associated plasma miRNAs, and nine A beta 1-42-associated serum miRNAs. These miRNAs were involved in AD-relevant biological processes, such as PI3K/AKT signaling. Based on this signaling pathway, we constructed an miRNA-gene target network, wherein miR-145-5p has been identified as a hub. Furthermore, we showed that miR-145-5p performs best in the prediction of both AD and MCI. Moreover, miR-145-5p also improved the prediction performance of the mini-mental state examination (MMSE) score. The performance of this miRNA was validated using different datasets including an RT-qPCR dataset from plasma samples of 23 MCI cases and 30 age-matched controls. These findings indicate that blood-circulating miRNAs that are associated with CSF biomarkers levels and specifically plasma miR-145-5p alone or combined with the MMSE score can potentially be used as noninvasive biomarkers for AD or MCI screening in the general population, although studies in other AD cohorts are necessary for further validation. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
ACS chemical neuroscience / American Chemical Society. - Washington, D.C, 2010, currens
| |
|
Publication
|
|
|
|
Washington, D.C
:
American Chemical Society
,
2024
| |
|
ISSN
|
|
|
|
1948-7193
| |
|
DOI
|
|
|
|
10.1021/ACSCHEMNEURO.3C00740
| |
|
Volume/pages
|
|
|
|
15
:5
(2024)
, p. 1042-1054
| |
|
ISI
|
|
|
|
001177339400001
| |
|
Pubmed ID
|
|
|
|
38407050
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (open access)
|
|
|
|
| |
|